The research leading to this publication has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 241959. We also acknowledge the ECNP child and adolescent neuropsychopharmacology network, the ECNP-Network Initiative and the reviewers of the manuscript.
Conflict of interest
Arango C. has been a consultant to or has received honoraria or grants from Abbot, AMGEN, AstraZeneca, Bristol-Myers Squibb, Caja Navarra, CIBERSAM, Fundación Alicia Koplowitz, Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Merck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Pfizer, Roche, Servier, Shire, Takeda and Schering Plough. Bonnot O. received honoraria from BMS et Actelion pharma. Buitelaar JK was in past 3 years a consultant to/member of advisory board of/and/or speaker for Janssen-Cilag BV, Eli Lilly, Shire, Novartis, Roche and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. Coghill D has received research funding from Lilly, Shire, Vifor was/is in the advisory board of Flynn Pharma, Janssen-Cilag, Pfizer, Shire, UCB, Vifor; has received honoraria for speaking from Flynn Pharma, Janssen-Cilag, Lilly, Medice, Novartis, Shire, UCB; Consultancy: Shire. Danckaerts M has received research funding or educational grants from or served as a speaker or adviser for Janssen-Cilag, Lilly, Novartis, Medice, and Shire. Dittmann RW is a former employee of Eli Lily & Company and owner of Eli Lilly stock, and currently holds the Eli Lilly Endowed Chair of Pediatric Psychopharmacology at the CIMH Mannheim, Germany. He has served in an advisory or consultancy role for Janssen-Cilag, Lilly, and Shire. He has received conference attendance support and received speaker’s fees from Lilly and Shire. He has been involved in clinical trials conducted by Ferring, Janssen-Cilag, Lilly, Otsuka, and Shire. He has received research funding from the NIMH, the European Union (EU FP7), the German Research Foundation (DFG), the German Ministries of Research and Education (BMBF) and Health (BMG/BfArM), and the Volkswagen Foundation. Falissard B, during the past 3 years BF has been consultant for the firms : E.Lilly, Servier, SANOFI, Pfizer, GSK, Roche, BMS, Merk, Genzyme, Astrazeneca, Lundbeck, Otsuka, Baxter, Stallergene, Daiichi, Almirall, Bayer, Novartis, BMS, Gilead, Astellas, Bayer. Fegert JM received research funding from EU, DFG, BMG, BMBF, BMFSFJ, diverse state and private foundations, European Academy, Gregorian University, Vatican, RAZCJD, Eli Lily Fundation, Janssen-Cilag, Medice, Celltech/USB, travel grants/honoraria/sponsoring from DFG, AACAP, NIMH/NIH, EU, Vatican, Goethe Institut, Pro Helvetica, Astra, Aventis, Bayer Bristol-MS, Celltech/USB, Janssen-Cilag, Lilly, Medice, Novartis, Pfizer, Ratiopharm, Sanofi-Synthelabo, Shire, VfA, Genericaverband. He was involved in clinical trails from Astra, Janssen-Cilag, Medice, Lilly, BMS, BMBF, Shire and Otsuka and in steering committees and DSMB for Pfizer, Lundbeck, Janssen-Cilag, Servier, Lilly and Celltech/USB. Kölch M is an employee of the University Hospital of Ulm and the Vivantes Netzwerk für Gesundheit Berlin. He received an unrestricted grant of the Eli Lilly International Foundation, research grants in the last 5 years by German Ministries for Family Affairs, Senior Citizens, Women and Youth, and for Research and Education (BMFFSJ, BMBF), Schweizer Bundesamt für Justiz, Boehringer-Ingelheim. He was or is clinical investigator or principal investigator in trials of Eli Lilly, Astra Zeneca, Janssen-Cilag. Lundbeck, Pascoe. Travel grants or payments for lectures by Janssen-Cilag, University of Rostock, DGKJPP, UCB, Europäische Akademie, various non-profit organisations. No stockholder or shareholder in pharmaceutical industry. Masi G was in the advisory boards for Eli Lilly, Shire and Novartis, has received research grants from Eli Lilly and Shire, and has been speaker for Eli Lilly, Shire, Lundbeck, Sanofi-Aventis and Novartis. Penzol MJ is involved in clinical trial from AMGEN. Purper-Ouakil D was in the past 3 years investigator for Boiron, Urgo, Speaker for Shire, BMS, Ardix, Novartis, had punctual scientific collaborations with Ardix, Shire and received research grants from EU (FP7), IREB (Institute for the research on alcohol related diseases) and AFSSAPS (French Medicine Agency). Schulze U received honoraria from Lilly, Pfizer, punctual consultation fee from Boehringer-Ingelheim, was or is involved in clinical trials from Janssen-Cilag, Medice, Lilly, Boehringer-Ingelheim and Lundbeck. Wong ICK has received research funding and honoraria from various pharmaceutical companies, including, Janssen-Cilag and Bristol-Myers Squibb (manufacturers of antipsychotic drug). IW is also a director of Healthcare Innovation Technology Service limited which received funding from the IMI for taking part in EU-AIMS project which investigates the use antipsychotic drugs in patients with ASD. Zuddas A has received research grants or served as speaker, adviser, or consultant for AstraZeneca, Bristol-Myers Squibb/Otsuka, Lilly, Lundbeck, Schering-Plough, Shire, and Vifor. All other authors (Bakker M, Carucci S, Castro-Fornieles J, Flamarique I, Glennon J, Hoekstra P, Murray M, Santosh PJ, Vicari S, Wan M) participate in EU-funded projects but declared no other conflict of interest.